Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer

被引：369

作者：

Bellahcene, Akeila ^{[2
]}

Castronovo, Vincent ^{[2
]}

Ogbureke, Kalu U. E. ^{[3
]}

Fisher, Larry W. ^{[4
]}

Fedarko, Neal S. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA

[2] Univ Liege, Metsastat Res Lab, B-4000 Cointe Ougree, Belgium

[3] Med Coll Georgia, Sch Dent, Dept Oral Biol, Augusta, GA 30912 USA

[4] NIH, Natl Inst Dent & Cranofacial Res, Dept Hlth & Human Serv, Bethesda, MD 20892 USA

来源：

NATURE REVIEWS CANCER | 2008年 / 8卷 / 03期

关键词：

D O I：

10.1038/nrc2345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Numerous components and pathways are involved in the complex interplay between cancer cells and their environment. The family of glycophosphoproteins comprising osteopontin, bone sialoprotein, dentin matrix protein 1, dentin sialophosphoprotein and matrix extracellular phosphoglycoprotein-small integrin-binding ligand N-linked glycoproteins (SIBLINGs)-are emerging as important players in many stages of cancer progression. From their detection in various human cancers to the demonstration of their key functional roles during malignant transformation, invasion and metastasis, the SIBLINGs are proteins with potential as diagnostic and prognostic tools, as well as new therapeutic targets.

引用

页码：212 / 226

页数：15

共 207 条

[1] Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells [J].

Adwan, H ;

Bäuerle, TJ ;

Berger, MR .

CANCER GENE THERAPY, 2004, 11 (02) :109-120

[2] Inflammation and cancer: How hot is the link? [J].

Aggarwal, Bharat B. ;

Shishodia, Shishir ;

Sandur, Santosh K. ;

Pandey, Manoj K. ;

Sethi, Gautam .

BIOCHEMICAL PHARMACOLOGY, 2006, 72 (11) :1605-1621

[3] Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin) [J].

Agnihotri, R ;

Crawford, HC ;

Haro, H ;

Matrisian, LM ;

Havrda, MC ;

Liaw, L .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (30) :28261-28267

[4]

Agrawal D, 2002, J NATL CANCER I, V94, P513

[5] Osteopontin identified as colon cancer tumor progression marker [J].

Agrawal, D ;

Chen, T ;

Irby, R ;

Quackenbush, J ;

Chambers, AF ;

Szabo, M ;

Cantor, A ;

Coppola, D ;

Yeatman, TJ .

COMPTES RENDUS BIOLOGIES, 2003, 326 (10-11) :1041-1043

[6] Plasma osteopontin levels are predictive of disease stage patients with transitional cell carcinoma of the bladder [J].

Ang, C ;

Chambers, AF ;

Tuck, AB ;

Winquist, E ;

Izawa, JI .

BJU INTERNATIONAL, 2005, 96 (06) :803-805

[7] Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells [J].

Angelucci, A ;

Festuccia, C ;

Gravina, GL ;

Muzi, P ;

Bonghi, L ;

Vicentini, C ;

Bologna, M .

PROSTATE, 2004, 59 (02) :157-166

[8] Immunohistochemical detection of osteopontin in advanced head-and-neck cancer:: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1α-related markers, and hemoglobin levels [J].

Bache, Matthias ;

Reddemann, Rolf ;

Said, Harun M. ;

Holzhausen, Hans-Juergen ;

Taubert, Helge ;

Becker, Axel ;

Kuhnt, Thomas ;

Haensgen, Gabriele ;

Dunst, Juergen ;

Vordermark, Dirk .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (05) :1481-1487

[9] Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers [J].

Bao, Li Hong ;

Sakaguchi, Hideki ;

Fujimoto, Jiro ;

Tamaya, Teruhiko .

JOURNAL OF BIOMEDICAL SCIENCE, 2007, 14 (03) :373-381

[10]

Barnes GL, 2003, CANCER RES, V63, P2631

← 1 2 3 4 5 6 7 8 9 10 →